These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 9279289)

  • 21. Delayed-type hypersensitivity and cross-reactivity to heparins and danaparoid: a prospective study.
    Grassegger A; Fritsch P; Reider N
    Dermatol Surg; 2001 Jan; 27(1):47-52. PubMed ID: 11231243
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiopulmonary bypass with danaparoid sodium and ancrod in heparin-induced thrombocytopenia.
    Kanagasabay RR; Unsworth-White MJ; Robinson G; Bevan D; Farnsworth G; Haxby EJ; Smith EE
    Ann Thorac Surg; 1998 Aug; 66(2):567-9. PubMed ID: 9725413
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thrombin generation assays are superior to traditional tests in assessing anticoagulation reversal in vitro.
    Gatt A; van Veen JJ; Woolley AM; Kitchen S; Cooper P; Makris M
    Thromb Haemost; 2008 Aug; 100(2):350-5. PubMed ID: 18690358
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The anticoagulant effect of heparan sulfate and dermatan sulfate.
    Teien AN; Abildgaard U; Höök M
    Thromb Res; 1976 Jun; 8(6):859-67. PubMed ID: 134464
    [No Abstract]   [Full Text] [Related]  

  • 25. Comparative antithrombotic and hemorrhagic effects of dermatan sulfate, heparan sulfate and heparin.
    Hoppensteadt D; Walenga JM; Fareed J
    Thromb Res; 1990 Nov; 60(3):191-200. PubMed ID: 2084948
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management of heparin-induced thrombocytopenia during continuous renal replacement therapy.
    Davenport A
    Am J Kidney Dis; 1998 Oct; 32(4):E3. PubMed ID: 10074589
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Successful use of danaparoid in treatment of heparin-induced thrombocytopenia during twin pregnancy.
    Gill J; Kovacs MJ
    Obstet Gynecol; 1997 Oct; 90(4 Pt 2):648-50. PubMed ID: 11770579
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Absence of in vitro cross-reaction of pentasaccharide with the plasma heparin-dependent factor of twenty-five patients with heparin-associated thrombocytopenia.
    Elalamy I; Lecrubier C; Potevin F; Abdelouahed M; Bara L; Marie JP; Samama M
    Thromb Haemost; 1995 Nov; 74(5):1384-5. PubMed ID: 8607131
    [No Abstract]   [Full Text] [Related]  

  • 29. Hirudin in heparin-induced thrombocytopenia.
    Lubenow N; Greinacher A
    Semin Thromb Hemost; 2002 Oct; 28(5):431-8. PubMed ID: 12420238
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Delayed-type skin reaction to the heparin-alternative danaparoid.
    Szolar-Platzer C; Aberer W; Kränke B
    J Am Acad Dermatol; 2000 Nov; 43(5 Pt 2):920-2. PubMed ID: 11044823
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The direct thrombin inhibitors (argatroban, bivalirudin and lepirudin) and the indirect Xa-inhibitor (danaparoid) increase fibrin network porosity and thus facilitate fibrinolysis.
    He S; Blombäck M; Bark N; Johnsson H; Wallén NH
    Thromb Haemost; 2010 May; 103(5):1076-84. PubMed ID: 20216982
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Heparin-induced thrombocytopenia-alternative anticoagulation in pregnancy and lactation.
    Lindhoff-Last E; Bauersachs R
    Semin Thromb Hemost; 2002 Oct; 28(5):439-46. PubMed ID: 12420239
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The in vitro anticoagulant effects of danaparoid, fondaparinux, and lepirudin in children compared to adults.
    Ignjatovic V; Summerhayes R; Yip YY; Monagle P
    Thromb Res; 2008; 122(5):709-14. PubMed ID: 18384841
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comparison of the activity of a heparan sulphate of defined molecular weight range (7500-15,000 Da) with heparin and dermatan sulphate.
    Gervasi GB; Catalani R; Bartoli C; Carpita G; Farina C; Gelso E
    Pharmacol Res; 1995 Jun; 31(6):331-6. PubMed ID: 8685069
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of factor X inhibition on coagulation activation and cytokine induction in human systemic inflammation.
    Hollenstein UM; Pernerstorfer T; Homoncik M; Hansen JB; Finzen H; Handler S; Jilma B
    J Infect Dis; 2002 Nov; 186(9):1270-6. PubMed ID: 12402196
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnosis of APC resistance in patients on standard or low molecular weight heparin.
    Gilmore G; Thom J; Baker RI
    Thromb Haemost; 1996 Feb; 75(2):372-3. PubMed ID: 8815593
    [No Abstract]   [Full Text] [Related]  

  • 37. Treatment of 51 pregnancies with danaparoid because of heparin intolerance.
    Lindhoff-Last E; Kreutzenbeck HJ; Magnani HN
    Thromb Haemost; 2005 Jan; 93(1):63-9. PubMed ID: 15630492
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Additional anticoagulant strategies for managing heparin-induced thrombocytopenia.
    Nawarskas JJ; Spinler SA
    Am J Health Syst Pharm; 1996 Apr; 53(8):945. PubMed ID: 8728386
    [No Abstract]   [Full Text] [Related]  

  • 39. The effect of danaparoid sodium (danaparoid) on endotoxin-induced experimental disseminated intravascular coagulation (DIC) in rats.
    Fujishima Y; Yokota K; Sukamoto T
    Thromb Res; 1998 Sep; 91(5):221-7. PubMed ID: 9755834
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Heparin-induced thrombocytopenia type II: perioperative management using danaparoid in a coronary artery bypass patient with renal failure.
    Westphal K; Martens S; Strouhal U; Matheis G; Lindhoff-Last E; Wimmer-Greinecker G; Lischke V
    Thorac Cardiovasc Surg; 1997 Dec; 45(6):318-20. PubMed ID: 9477469
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.